Biological Insights into Myeloma and Other B Cell Malignancies
1Dana-Farber Cancer Institute, Boston, USA
2Magna Graecia University of Catanzaro, Catanzaro, Italy
3University of Genoa, Genoa, Italy
4University of Navarra, Pamplona, Spain
5Washington University, Saint Louis, USA
Biological Insights into Myeloma and Other B Cell Malignancies
Description
Despite advances in multiple myeloma (MM) therapy, the majority of patients eventually die from the disease. Although various aspects of MM pathobiology are well established, there is increasing awareness that MM cell-bone marrow stromal cell (BMSC) interactions support growth and survival of the tumor cells and lead to the development of drug resistance. Nonetheless, MM cells accumulate various genetic and epigenetic abnormalities that drive the malignant phenotype and confer distinct biologic sequelae and disease outcomes. This has prompted continued search to understand molecular changes in MM and potential ways to target them.
This special issue will focus on the current understanding of MM biology with emphasis on identification and validation of new targets and pathways for prognostic and therapeutic application.
We invite authors to contribute original research articles as well as review articles.
Potential topics include, but are not limited to:
- Therapeutic relevance of novel targets regulating tumor cell growth, survival, and drug resistance in vitro and in vivo
- Development of drug combinations
- Myeloma bone disease
- Transcriptional regulation in myeloma and other B cell malignancies
- Role of epigenetics in the biology of multiple myeloma
- MicroRNA as potential target for gene therapy
- Genome instability in MM disease progression and prognosis
- Immunomodulation in myeloma